Senior Executives Highlight Expansions, M&A at the DCAT Member Company Announcement Forum 

Senior executives from DCAT Member Companies highlighted their companies’ major news at the DCAT Member Company Announcement Forum at DCAT Week.

Senior executives from DCAT Member Companies highlighted their companies’ major news at the DCAT Member Company Announcement Forum at DCAT Week.

DCAT Member Companies take to the podium at DCAT Week
Senior executives from DCAT Member Companies highlighted their companies major news at the DCAT Member Company Announcement Forum at DCAT Week, the flagship event of the Drug, Chemical & Associated Technologies Association (DCAT). Companies reported the latest in expansion plans and mergers and acquisitions (M&A) across the bio/pharmaceutical manufacturing value chain: from drug substances (small-molecules and biologics) to drug products (solid dosage and injectable product forms). In all, 20 companies took to the podium to make their announcements. The program kicked off DCAT Week on Monday March 18th, 2024. 

Expansions in biomanfacturing, both biologic-based drug substances and cell and gene therapies, was a major theme. Companies making news announcements in this area included Samsung Biologics, Fujifilm Diosynth Biotechnologies, Evotec, Seqens, and Aragen Life Sciences. 

Expansions in manufacturing for small-molecule active pharmaceutical ingredients (APIs), including high-potency APIs, and other specialized APIs, was another key area of investment with several companies announcing expansion plans, recently completed expansions, or soon-to-be-completed expansions. These companies included Cambrex, AGC Pharma Chemicals, Porton, Polpharma API, and ST Pharm.   

On the drug-product side, expansions in sterile drug manufacturing/injectables was also an area of investment activity announced at the DCAT Member Company Announcement Forum at DCAT Week. Companies making news in this area included Simtra BioPharma Solutions, Kindeva Drug Delivery, Oncomed Manufacturing, and Adragos Pharma.  

Crossing more than one manufacturing area are end-to-end providers, which had expansion news for both drug-substance and drug-product manufacturing. These end-to-end providers included announcements by Thermo Fisher Scientific, Noramco, WuXi STA, CordenPharma, BSP Pharmaceuticals, and Enzene Biosciences.  

Details of each company’s announcement can be found below.  

Samsung Biologics Provides Update on Billion-Dollar-Plus Biomanufacturing Expansions

Thermo Fisher Scientific Highlights Multiple Expansions: Sterile Drug-Product & Biologics Mfg

Noramco Updates Integration of Acquisition of Cambrex’s Drug-Product Business

Simtra BioPharma Solutions Announces $250-M  Expansion of Sterile Fill-Finish Mfg Campus

Fujifilm Diosynth Biotechnologies Updates Multi-Billion-Dollar Biomanufacturing Expansions

WuXi STA Launches New Small-Molecule API Facility; Expands Peptides, Oligonucleotides Capacity; Updates Drug-Product Expansions

CordenPharma Announces Mfg Expansions in Peptides, Solid Dosage Products & LNP

AGC Pharma Chemicals Investing $100-M-Plus To Expand Small-Molecule API, High-Potency API Mfg

Evotec Subsidiary Just-Evotec Biologics Adding New Facility for Continuous Biomanufacturing

ST Pharm Investing $110 M To Expand Oligonucleotide Mfg Capacity

Kindeva Drug Delivery Investing $150 M-Plus for New Fill–Finish Facility; Acquires Nasal-Drug Delivery Company Summit Biosciences

Cambrex Nears Completion of Multi-Year, $100-M Small-Molecule API Expansion

Seqens Enters Cell- & Gene-Therapy Market With Acquisition of CELLforCURE

Porton Expanding Small-Molecule API Manufacturing

BSP Pharmaceuticals Announces Multi-Year, $576-M Expansion for Cytotoxic & Non-Cytotoxic Products

Enzene Biosciences Adding New Facility for Continuous Biomanufacturing

Oncomed Manufacturing To Commission New Production Line for Syringes

Adragos Pharma Expands Drug-Product Capabilities with Key Acquisitions

Polpharma API Expanding High-Potency API Manufacturing

Aragen Life Sciences Proceeds with Biomanufacturing Expansion

Recent Feature Articles

What’s Trending Inside the CDMO/CMO Market?

What are key trends shaping the market for bio/pharmaceutical outsourcing? DCAT Value Chain Insights takes an inside look into the market drivers, trends, and key activity shaping the CDMO/CMO sector in small-molecules, biologics, and drug products.

US Bio/Pharma Market: Is Stronger Growth Ahead?

The US bio/pharma market showed positive signs in 2023, despite a decline in spending on COVID-19 vaccines and products. Overall, the US market grew by 2.3% last year, and by 9.9%, excluding COVID-19 products. What’s projected in the near term?

AI Front and Center for Supply Chain Management 

How will artificial intelligence (AI) shape sourcing and supply chain management? A newly released study by DCAT and a panel discussion at DCAT Week examined AI’s potential, the types of projects and activities for which AI may be applied, and its challenges to its use and adoption.

The CDMO/CMO Report: Injectable Drugs

Demand for fill–finish capacity and sterile manufacturing is high, led by bio/pharma companies’ product portfolios and development pipelines in biologics and other key products, such as GLP-1 drugs. A roundup of the latest expansions by CDMOs/CMOs.